Safe SA (France)

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR001400F1V2
EUR
1.14
0.04 (3.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Safe SA (France) stock-summary
stock-summary
Safe SA (France)
Pharmaceuticals & Biotechnology
Safe Orthopaedics SA is a France-based company principally engaged in the medical devices industry. The Company focuses on the development and commercialization of products for use in spinal surgery. It provides a range of implants and ready to use instrument kits. The Company's product portfolio comprises SteriSpine PS, which is the Pedicle Screw System; and SteriSpine LC, which is the Lumbar Cage System that enables safe implant positioning, as well as access, insertion and placement of the implant. The Company's products are equipped with quick change handle, dual trial and impact removal, among others. The Company mainly uses polyarylamid material, which is a polymar with 50% glass fibers.
Company Coordinates stock-summary
Company Details
Parc des Bellevues, Allee R. Luxemburg, Eragny sur Oise ERAGNY None : 95610
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 1 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Pierre Dumouchel
Chairman of the Board, Chief Executive Officer, Co-Founder
Mr. Francois-Henri Reynaud
Administrative and Financial Director, Director
Mr. Thomas Droulout
Director, Technical Director
Mr. Philippe Chene
Independent Director
Mr. Ismael Nujurally
Independent Director
Mr. Philippe Oak
Independent Director
Mr. Dominique Petit
Independent Director
Mr. Philippe Petrou
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 0 Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.32

stock-summary
Return on Equity

153.58%

stock-summary
Price to Book

-0.00